Evaluate the Efficacy and Safety of TG-2349 in Subjects With Hepatitis C Infection
Condition: Hepatitis C, Chronic
MeSH terms: Hepatitis A; Hepatitis C; Hepatitis C, Chronic; Hepatitis
Study type: Interventional
Phase: Phase 2

Summary: 
      A Phase 2, Multicenter, Randomized, Open-label, Dose-ranging Study to Evaluate the Efficacy
      and Safety of TG-2349 in Combination with Peg-interferon and Ribavirin in Treatment Naïve
      East Asian Subjects with Chronic Hepatitis C Virus Genotype 1b Infection.
    

Detailed description: 
      It is a multicenter, randomized, open-label study to evaluate the safety, tolerability, and
      antiviral efficacy of two different doses of TG-2349 combined with Peg-interferon (IFN) and
      Ribavirin (RBV) in HCV-GT1b treatment naïve East Asian subjects. The treatment duration of
      TG-2349+IFN+RBV is 12 weeks, with or without an additional 12-week treatment of IFN+RBV,
      depending on HCV RNA level at On-Treatment Week 4. Approximately 24 subjects will be
      randomized (1:1) to one of the following 2 treatment groups:

        -  Group I (n=12): 200 mg TG-2349 (2 capsules) + IFN + RBV

        -  Group II (n=12): 400 mg TG-2349 (4 capsules) + IFN + RBV Randomization will be
           stratified by IL28B genotype "CC" or "non-CC". Subjects with HCV RNA < LLOQ (lower limit
           of quantification), TD (target detected) or TND (target not detected) at Week 4 will
           receive 12 weeks of TG-2349+IFN+RBV treatment. Subjects with HCV RNA ≥ LLOQ but < 100
           IU/mL at Week 4 will receive 12 weeks of TG-2349+IFN+RBV treatment followed by an
           additional 12 weeks of IFN+RBV treatment. However, subjects with HCV RNA ≥ 100 IU/mL at
           Week 4 will discontinue the study treatment and complete the Early-Termination (ET)
           visit. The study will be terminated if 3 or more of the first 12 subjects enrolled
           across both Groups I and II, or ≥ 25% of subjects thereafter, fail to respond to
           treatment (i.e., confirmed on-treatment virologic failure or post-treatment relapse).
           Patients, except those who have achieved SVR12, will be offered the standard of care
           with Peg-interferon and Ribavirin for duration of 24, 48, or 72 weeks based on Taiwan's
           regulatory guideline and principal investigator's judgment.
    

Intervention name(s): TG-2349; Ribavirin; Interferon Alfa-2a
Intervention type(s): Drug; Drug; Drug
Intervention description(s): TG-2349 (Furaprevir) is available as a Swedish orange capsule (size 0) for oral administration. Each capsule contains an equivalent of 100 mg of TG-2349 spray dried solid (SDD) and the following inactive ingredients: microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, magnesium stearate, and colloidal silicon oxide.; RBV (Ribavirin or COPEGUS®) is available as a light pink to pink colored, flat, oval-shaped, film-coated tablet for oral administration. Each tablet contains 200 mg of ribavirin and the following inactive ingredients: pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, cornstarch, and magnesium stearate. The coating of the tablet contains Chromatone-P® or Opadry® Pink (made by using hydroxypropyl methyl cellulose, talc, titanium dioxide, synthetic yellow iron oxide, and synthetic red iron oxide), ethyl cellulose (ECD-30), and triacetin.; IFN (Interferon, Peg-interferon alpha-2a or PEGASYS®) is available as a sterile, preservative-free, colorless to light yellow injectable solution administered subcutaneously.
Each prefilled syringe of 180 μg/0.5 mL IFN (expressed as the amount of interferon alfa-2a) also contains acetic acid (0.0231 mg), benzyl alcohol (5 mg), polysorbate 80 (0.025 mg), sodium acetate trihydrate (1.3085 mg), and sodium chloride (4 mg) at pH 6 ± 0.5.
Intervention MeSH terms: Interferons; Ribavirin; Interferon-alpha; Interferon alpha-2
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment